Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adipose-Derived Stromal Vascular Fraction Cell Therapy to Treat Post COVID-19 Respiratory Distress - An Early Feasibility Study

NCT06940765 is registered in ClinicalTrials.gov with GID BIO, Inc. as lead sponsor.

NCT NCT06940765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06940765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adipose-Derived Stromal Vascular Fraction Cell Therapy to Treat Post COVID-19 Respiratory Distress - An Early Feasibility Study
Lead sponsor
GID BIO, Inc.
Phase
Not applicable
Overall status
Withdrawn
Start date
September 30, 2021
Completion date
May 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid19